HKSE - Delayed Quote HKD
PURAPHARM (1498.HK)
0.480
-0.010
(-2.04%)
At close: 1:57:50 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
382,090
382,090
406,859
448,069
659,592
Cost of Revenue
176,948
176,948
190,230
185,365
236,239
Gross Profit
205,142
205,142
216,629
262,704
423,353
Operating Expense
221,980
221,980
253,725
306,980
380,342
Operating Income
-16,838
-16,838
-37,096
-44,276
43,011
Net Non Operating Interest Income Expense
-23,365
-23,365
-27,114
-23,708
-26,667
Pretax Income
-29,144
-29,144
-102,312
-119,182
-117,192
Tax Provision
6,295
6,295
3,769
1,032
4,685
Net Income Common Stockholders
-35,439
-35,439
-106,081
-120,214
-121,877
Diluted NI Available to Com Stockholders
-35,439
-35,439
-106,081
-120,214
-121,877
Basic EPS
-0.09
--
-0.27
-0.30
-0.31
Diluted EPS
-0.09
--
-0.27
-0.30
-0.31
Basic Average Shares
395,052.941
--
395,052.941
394,584.833
393,732.673
Diluted Average Shares
395,052.941
--
395,052.941
394,584.833
393,732.673
Rent Expense Supplemental
--
--
2,220
4,298
--
Total Expenses
398,928
398,928
443,955
492,345
616,581
Net Income from Continuing & Discontinued Operation
-35,439
-35,439
-106,081
-120,214
-121,877
Normalized Income
-43,126.010
-43,126.010
-88,354.370
-109,157.765
14,834.120
Interest Income
349
349
293
475
360
Interest Expense
23,714
23,714
27,407
24,183
27,027
Net Interest Income
-23,365
-23,365
-27,114
-23,708
-26,667
EBIT
-5,430
-5,430
-74,905
-94,999
-90,165
EBITDA
49,156
49,156
-26,314
-46,338
-40,026
Reconciled Cost of Revenue
176,948
176,948
190,230
185,365
236,239
Reconciled Depreciation
54,586
54,586
48,591
48,661
50,139
Net Income from Continuing Operation Net Minority Interest
-35,439
-35,439
-106,081
-120,214
-121,877
Total Unusual Items Excluding Goodwill
9,206
9,206
-17,578
-13,241
-83,072
Total Unusual Items
9,206
9,206
-14,529
-13,241
-15,726
Normalized EBITDA
39,950
39,950
-11,785
-33,097
-24,300
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,518.990
1,518.990
-2,900.370
-2,184.765
-13,706.880
12/31/2021 - 7/8/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade